Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dihydroergocornine
- Development stage
- Unknown
- Lead developer
- Sandoz
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Dihydroergocornine is a semisynthetic ergot alkaloid and one of the three main components of ergoloid mesylates (also known as Hydergine). It is derived from ergocornine by hydrogenation of double bonds in lysergic acid. Dihydroergocornine has been used primarily to treat dementia and age-related cognitive impairment, including conditions such as Alzheimer's disease. Its mechanism of action is not fully established but it exhibits sympatholytic and hypotensive properties, decreases cerebral blood flow and vascular resistance, and may help maintain cerebral metabolic homeostasis. Pharmacologically, it acts as a dopamine agonist with possible activity at serotonergic receptors and alpha-adrenoreceptors[1][2][3][7].
- Other names
- 9,10-dihydroergocornine
02
Targets
ADRA1 (Alpha-1 adrenergic receptor family)DRD (Dopamine receptors)5-HT (Serotonin receptors)ADRA1A (α1A)
Beyond the preview
Go deeper on dihydroergocornine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dihydroergocornine.